GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
25 Mar 2026 03:30 PM
RNS
Director/PDMR Shareholding
25 Mar 2026 01:00 PM
RNS
Notice of AGM
25 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
24 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
23 Mar 2026 03:30 PM
RNS
Director/PDMR Shareholding
23 Mar 2026 03:00 PM
RNS
Admission to Trading
23 Mar 2026 07:00 AM
RNS
GSK Lung Cancer ADC Gets Japan Orphan Drug Status
23 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
20 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
19 Mar 2026 12:00 PM
RNS
Lynavoy (linerixibat) approved by US FDA
19 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
18 Mar 2026 03:30 PM
RNS
Director/PDMR Shareholding
18 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
17 Mar 2026 03:30 PM
RNS
Director/PDMR Shareholding
17 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
16 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
13 Mar 2026 10:31 AM
RNS
US FDA approves Arexvy for adults 18-49 AIR
13 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
12 Mar 2026 03:30 PM
RNS
Director/PDMR Shareholding
12 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
11 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
10 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
09 Mar 2026 03:00 PM
RNS
Board Committee Change
09 Mar 2026 07:00 AM
RNS
GSK and Alfasigma agree global linerixibat rights
09 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
06 Mar 2026 02:21 PM
RNS
Filing of GSK plc 2025 Annual Report on Form 20-F
06 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
05 Mar 2026 10:00 AM
RNS
GSK publishes Annual Report 2025
05 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
04 Mar 2026 03:30 PM
RNS
Director/PDMR Shareholding
04 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
03 Mar 2026 03:00 PM
RNS
GSK completes acquisition of RAPT Therapeutics
03 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
02 Mar 2026 03:00 PM
RNS
Total Voting Rights
02 Mar 2026 07:00 AM
RNS
Transaction in Own Shares
27 Feb 2026 03:30 PM
RNS
Director/PDMR Shareholding
27 Feb 2026 07:00 AM
RNS
Transaction in Own Shares
26 Feb 2026 07:05 AM
RNS
Linerixibat accepted for priority review in China
26 Feb 2026 07:00 AM
RNS
Bepirovirsen accepted for Japan regulatory review
26 Feb 2026 07:00 AM
RNS
Transaction in Own Shares
25 Feb 2026 04:54 PM
RNS
Director/PDMR Shareholding
25 Feb 2026 03:30 PM
RNS
Director/PDMR Shareholding
25 Feb 2026 07:00 AM
RNS
GSK enters agreement to acquire 35Pharma
25 Feb 2026 07:00 AM
RNS
Transaction in Own Shares
24 Feb 2026 03:30 PM
RNS
Director/PDMR Shareholding
24 Feb 2026 07:00 AM
RNS
Transaction in Own Shares
23 Feb 2026 07:00 AM
RNS
Transaction in Own Shares
20 Feb 2026 03:30 PM
RNS
Director/PDMR Shareholding
20 Feb 2026 07:00 AM
RNS
Transaction in Own Shares

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings